U.S. markets close in 2 minutes
  • S&P 500

    4,122.01
    -19.58 (-0.47%)
     
  • Dow 30

    33,709.81
    +32.54 (+0.10%)
     
  • Nasdaq

    13,847.42
    -148.68 (-1.06%)
     
  • Russell 2000

    2,248.31
    +19.39 (+0.87%)
     
  • Crude Oil

    62.93
    +2.75 (+4.57%)
     
  • Gold

    1,736.70
    -10.90 (-0.62%)
     
  • Silver

    25.46
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1983
    +0.0029 (+0.24%)
     
  • 10-Yr Bond

    1.6380
    +0.0150 (+0.92%)
     
  • GBP/USD

    1.3781
    +0.0028 (+0.21%)
     
  • USD/JPY

    108.9000
    -0.1480 (-0.14%)
     
  • BTC-USD

    62,160.72
    -616.45 (-0.98%)
     
  • CMC Crypto 200

    1,341.71
    -34.06 (-2.48%)
     
  • FTSE 100

    6,939.58
    +49.09 (+0.71%)
     
  • Nikkei 225

    29,620.99
    +82.29 (+0.28%)
     

Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Exelixis Inc (NASDAQ: EXEL) has reported new data from the Phase 2 (PAPMET) study evaluating CABOMETYX (cabozantinib) compared with Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer.

  • Exelixis presented the data at the American Society of Clinical Oncology's Genitourinary Cancers Symposium. It will publish the findings simultaneously in the Lancet.

  • CABOMETYX demonstrated Median progression-free survival of 9.0 months (n=44) versus 5.6 months with sunitinib (n=46), trial's primary endpoint. The overall response rate was 23% for CABOMETYX versus 4% for sunitinib. Median overall survival was 20 months for cabozantinib and 16.4 months for sunitinib, which did not reach statistical significance.

  • Enrollment into additional arms of the study examining the use of crizotinib or savolitinib compared to sunitinib was halted early based on predefined interim futility analyses.

  • On the safety front, the most common severe/life-threatening adverse events with CABOMETYX were hypertension (32%), hand-foot syndrome (20%), and fatigue (13%). One death, secondary to a thromboembolic event, was reported for a patient receiving CABOMETYX.

  • The discontinuation rate of study medications due to treatment-related adverse events was 24% for sunitinib and 23% for CABOMETYX.

  • Last week, the Company reported Cabometyx combined with Bristol Myers Squibb's Opdivo doubled median progression-free survival (17.0 months vs. 8.3 months) compared to sunitinib, the trial's primary endpoint, in the first-line treatment of advanced renal cell carcinoma.

  • Price Action: EXEL gained 2.24% at $22.4 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.